Risks, Burdens, Benefits of an Infused Amyloid Monoclonal Antibody Compared to an Oral Cholinesterase Inhibitor

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Risks, Burdens, Benefits of an Infused Amyloid Monoclonal Antibody Compared to an Oral Cholinesterase Inhibitor

By Montefiore Einstein FEATURING Aviva Cantor, Gary J. Kennedy

467 views

April 18, 2024

Disclaimer: On July 2, 2024 the FDA approved Kisunla (donanemab-azbt) injection for the treatment of ...
read more ↘ Alzheimer’s disease. Treatment should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials.
Aduhelm (aducanumab) has been discontinued from development and commercialization as of January 2024.
↖ read less

Comments 0